In military veterans with traumatic brain injury, treatment with ibogaine plus magnesium led to dramatic clinical improvements and a favorable safety profile; further studies with state-of-the art safety monitoring will be crucial to unlocking the potential benefits of this psychedelic compound.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Suitt, T. H. High Suicide Rates Among United States Service Members and Veterans of the Post-9/11 Wars https://go.nature.com/3RQJ9Qm (Brown Univ., 2021).
Siddiqi, S. H. et al. J. Neurotrauma 36, 1361–1374 (2019).
Siddiqi, S. H. et al. Sci. Transl. Med. 15, eabn0441 (2023).
Mosca, A. et al. Curr. Neuropharmacol. 21, 2178–2194 (2023).
Cherian, K. et al. Nat. Med. https://doi.org/10.1038/s41591-023-02705-w (2024).
Canady, V. A. Ment. Health Wkly 33, 3–5 (2023).
Jones, B. D. M. et al. JAMA Netw. Open 4, e2125531–e2125531 (2021).
Sonawalla, S. B. & Rosenbaum, J. F. Dialogues Clin. Neurosci. 4, 105–113 (2002).
Palm, S. T. et al. Preprint at bioRxiv https://doi.org/10.1101/2023.06.05.543261 (2023).
Meisner, J. A., Wilcox, S. R. & Richards, J. B. Ther. Adv. Psychopharmacol. 6, 95–98 (2016).
O’Brien, B., Wilkinson, S. T. & Mathew, S. J. Am. J. Psychiatry 179, 393–394 (2022).
Acknowledgements
Disclaimers: The opinions and assertions expressed herein are those of the authors and do not necessarily reflect the official policy or position of the Uniformed Services University, the Department of Defense, the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., or other government agency.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
D.L.B.: employee of the US Department of Defense. Research currently funded by Department of Defense. Holds equity in Inner Cosmos LLC. Receives royalties from sales of Concussion Care Manual (Oxford Univ. Press) and honoraria from Mary Ann Liebert, Inc., publisher of the Journal of Neurotrauma, for services as editor-in-chief. Performs consulting for Pfizer Inc., Intellectual Ventures, Signum Nutralogix, Kypha Inc., Sage Therapeutics, iPerian Inc., Navigant, Avid Radiopharmaceuticals (Eli Lilly & Co.), the St. Louis County Public Defender, the United States Attorney’s Office, the St. Louis County Medical Examiner, GLG and Stemedica. None of these entities were directly involved in the present work. S.H.S.: owner of intellectual property involving the use of brain connectivity to target transcranial magnetic stimulation, scientific consultant for Magnus Medical, performs investigator-initiated research funding from Neuronetics and Brainsway, receives speaking fees from Brainsway and Otsuka (for PsychU.org) and is a shareholder in Brainsway (publicly traded) and Magnus Medical (not publicly traded). None of these entities were directly involved in the present work.
Rights and permissions
About this article
Cite this article
Brody, D.L., Siddiqi, S.H. An ancient psychedelic for traumatic brain injury. Nat Med 30, 342–343 (2024). https://doi.org/10.1038/s41591-023-02759-w
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-023-02759-w